eCite Digital Repository

Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials


Wu, J and Zhu, Z and Yu, Q and Ding, C, Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials, Expert Opinion on Investigational Drugs, 28, (12) pp. 1113-1123. ISSN 1354-3784 (2019) [Refereed Article]

Copyright Statement

Copyright 2019 Informa UK Limited, trading as Taylor & Francis Group

DOI: doi:10.1080/13543784.2019.1692812


Introduction: Rheumatoid arthritis (RA) is a chronic, refractory disorder caused by autoimmunity in the synovial joints. Disease-modifying anti-rheumatic drugs (DMARDs) and biologicals offer remission in only two-thirds of RA patients within 3 months, hence new therapeutic approaches are necessary. Tyrosine kinase inhibitors (TKIs) are newly developed small molecule drugs which have demonstrated encouraging results in this disease.

Areas covered: The key findings from phase I and II clinical trials that have investigated the use of novel TKIs in the treatment of RA are discussed. We examined the literature published between January 2014 to January 2019 using electronic databases including PubMed, Web of Science, Medline, Embase, and Google Scholar. Additional information about phase I and II trials on the website up to January 2019 was also retrieved.

Expert opinion: JAK inhibitors are promising drugs with sound efficacy and acceptable safety and may be beneficial to patients who do not respond to DMARDs and biologicals. The response rates among RA patients to TKIs are diverse; genetic and environmental factors may be involved in the varying responses which are closely related to the pathogenesis of RA. Future studies may reveal the underlying mechanisms of resistance and non-response.

Item Details

Item Type:Refereed Article
Keywords:Brutonís tyrosine kinases, Janus kinase, rheumatoid arthritis, disease-modifying anti-rheumatic drugs, spleen tyrosine kinases, tyrosine kinase inhibitor
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Rheumatology and arthritis
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Ding, C (Professor Chang-Hai Ding)
ID Code:138036
Year Published:2019
Web of Science® Times Cited:5
Deposited By:Menzies Institute for Medical Research
Deposited On:2020-03-21
Last Modified:2020-07-28

Repository Staff Only: item control page